JP2020520949A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020520949A5 JP2020520949A5 JP2019564449A JP2019564449A JP2020520949A5 JP 2020520949 A5 JP2020520949 A5 JP 2020520949A5 JP 2019564449 A JP2019564449 A JP 2019564449A JP 2019564449 A JP2019564449 A JP 2019564449A JP 2020520949 A5 JP2020520949 A5 JP 2020520949A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- salt
- phenyl
- compound
- cooh
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 19
- 150000003839 salts Chemical class 0.000 claims 18
- -1 hydroxy, amino Chemical group 0.000 claims 16
- 125000000217 alkyl group Chemical group 0.000 claims 12
- 229910052739 hydrogen Inorganic materials 0.000 claims 11
- 239000001257 hydrogen Substances 0.000 claims 11
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 10
- 229910052736 halogen Inorganic materials 0.000 claims 10
- 150000002367 halogens Chemical class 0.000 claims 10
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 10
- 125000002947 alkylene group Chemical group 0.000 claims 9
- 125000000753 cycloalkyl group Chemical group 0.000 claims 9
- 125000004093 cyano group Chemical group *C#N 0.000 claims 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 7
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 6
- 125000003342 alkenyl group Chemical group 0.000 claims 6
- 125000000304 alkynyl group Chemical group 0.000 claims 6
- 150000002431 hydrogen Chemical class 0.000 claims 6
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 5
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 claims 4
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 claims 4
- 125000001424 substituent group Chemical group 0.000 claims 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 4
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 3
- 125000003545 alkoxy group Chemical group 0.000 claims 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims 3
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 3
- 230000001476 alcoholic effect Effects 0.000 claims 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 2
- 230000002438 mitochondrial effect Effects 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- 208000024891 symptom Diseases 0.000 claims 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
- 125000006276 2-bromophenyl group Chemical group [H]C1=C([H])C(Br)=C(*)C([H])=C1[H] 0.000 claims 1
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 claims 1
- 125000006304 2-iodophenyl group Chemical group [H]C1=C([H])C(I)=C(*)C([H])=C1[H] 0.000 claims 1
- 125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 claims 1
- 125000004800 4-bromophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Br 0.000 claims 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 102000004877 Insulin Human genes 0.000 claims 1
- 108090001061 Insulin Proteins 0.000 claims 1
- 206010022489 Insulin Resistance Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 206010063837 Reperfusion injury Diseases 0.000 claims 1
- 239000012190 activator Substances 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 208000010706 fatty liver disease Diseases 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 230000014101 glucose homeostasis Effects 0.000 claims 1
- 125000004438 haloalkoxy group Chemical group 0.000 claims 1
- 125000001188 haloalkyl group Chemical group 0.000 claims 1
- 229940125396 insulin Drugs 0.000 claims 1
- 208000012947 ischemia reperfusion injury Diseases 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims 1
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 230000001568 sexual effect Effects 0.000 claims 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762509249P | 2017-05-22 | 2017-05-22 | |
| US62/509,249 | 2017-05-22 | ||
| PCT/US2018/033901 WO2018217757A1 (en) | 2017-05-22 | 2018-05-22 | Compositions and methods for preparing and using mitochondrial uncouplers |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020520949A JP2020520949A (ja) | 2020-07-16 |
| JP2020520949A5 true JP2020520949A5 (enExample) | 2021-07-26 |
Family
ID=62567845
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019564449A Pending JP2020520949A (ja) | 2017-05-22 | 2018-05-22 | 組成物、並びにミトコンドリア脱共役剤を調製及び使用する方法 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US11896591B2 (enExample) |
| EP (1) | EP3630115B1 (enExample) |
| JP (1) | JP2020520949A (enExample) |
| WO (1) | WO2018217757A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4086242A1 (en) | 2017-01-06 | 2022-11-09 | Rivus Pharmaceuticals, Inc. | 5-[(2,4-dinitrophenoxy)methyl]-1-methyl-2-nitro-l h-imidazole and its pharmaceutical use |
| MX2020011050A (es) * | 2018-04-20 | 2021-03-09 | Virginia Tech Intellectual Properties Inc | Imidazopiridinas útiles como desacopladores mitocondriales. |
| EP4482494A4 (en) * | 2022-02-21 | 2026-02-25 | Univ Colorado Regents | RE-SENSITIZATION OF MULTI-DRUG-RESISTANT GRAM-NEGATIVE (MDR) BACTERIA TO COLISTIN USING IONOPHORES |
| WO2024006055A1 (en) * | 2022-06-30 | 2024-01-04 | University Of Florida Research Foundation, Incorporated | Small molecule broad-spectrum antibiotics |
| CN116535420A (zh) * | 2023-04-21 | 2023-08-04 | 西安近代化学研究所 | 一种5,6-二氯呋咱并[3,4-b]吡嗪的合成方法 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL109529C (enExample) | 1959-03-14 | |||
| FR2501680A1 (fr) | 1981-03-12 | 1982-09-17 | Elf Aquitaine | Synthese de tetra mercaptides stanniques |
| US4472840A (en) | 1981-09-21 | 1984-09-25 | Jefferies Steven R | Method of inducing osseous formation by implanting bone graft material |
| US4559157A (en) | 1983-04-21 | 1985-12-17 | Creative Products Resource Associates, Ltd. | Cosmetic applicator useful for skin moisturizing |
| LU84979A1 (fr) | 1983-08-30 | 1985-04-24 | Oreal | Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux |
| US4820508A (en) | 1987-06-23 | 1989-04-11 | Neutrogena Corporation | Skin protective composition |
| US5606019A (en) | 1987-10-29 | 1997-02-25 | Protien Polymer Technologies, Inc. | Synthetic protein as implantables |
| GB2215209B (en) | 1988-03-14 | 1992-08-26 | Osmed Inc | Method and apparatus for biodegradable, osteogenic, bone graft substitute device |
| US4992478A (en) | 1988-04-04 | 1991-02-12 | Warner-Lambert Company | Antiinflammatory skin moisturizing composition and method of preparing same |
| US4938949A (en) | 1988-09-12 | 1990-07-03 | University Of New York | Treatment of damaged bone marrow and dosage units therefor |
| JPH0327172A (ja) | 1989-06-19 | 1991-02-05 | Nissan Chem Ind Ltd | 布の漂白方法 |
| US5645591A (en) | 1990-05-29 | 1997-07-08 | Stryker Corporation | Synthetic bone matrix |
| US20090131445A1 (en) * | 2004-10-14 | 2009-05-21 | Compass Pharmaceuticals Llc | Furazano '3, 4-B! Pyrazines and Their Use as Anti-Tumor Agents |
| WO2007008541A2 (en) * | 2005-07-08 | 2007-01-18 | Kalypsys, Inc. | Cellular cholesterol absorption modifiers |
| JP2010500994A (ja) * | 2006-08-16 | 2010-01-14 | エグゼリクシス， インコーポレイテッド | Ｐｉ３ｋおよびｍｅｋモジュレーターを使用する方法 |
| KR101951851B1 (ko) * | 2009-12-14 | 2019-02-26 | 유디씨 아일랜드 리미티드 | 디아자벤즈이미다졸로카르벤 리간드를 포함하는 금속 착물 및 ｏｌｅｄ에서의 그의 용도 |
| WO2013192388A1 (en) * | 2012-06-20 | 2013-12-27 | University Of Virginia Patent Foundation | Compositions and methods for regulating glucose homeostasis and insulin action |
-
2018
- 2018-05-22 US US16/615,567 patent/US11896591B2/en active Active
- 2018-05-22 EP EP18730588.3A patent/EP3630115B1/en active Active
- 2018-05-22 JP JP2019564449A patent/JP2020520949A/ja active Pending
- 2018-05-22 WO PCT/US2018/033901 patent/WO2018217757A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020520949A5 (enExample) | ||
| JP6986022B2 (ja) | Ｆｘｒアゴニストを使用するための方法 | |
| ES2642216T3 (es) | Compuestos de hidroxilo y composiciones para el control del colesterol y utilizaciones correspondientes | |
| RU2702109C1 (ru) | Комбинированная терапия для лечения инфекций вгв | |
| ES2752039T3 (es) | Agente terapéutico para la dislipidemia | |
| RU2485131C2 (ru) | Производные пиридина, замещенные гетероциклическим кольцом и фосфоноксиметильной группой и содержащие их противогрибковые средства | |
| RU2009126745A (ru) | Производные сульфонилфенил-2н-{1,2,4}оксадиазол-5-она, способы их получения и их применение в качестве фармацевтических средств | |
| JP2004525179A (ja) | ジペプチジルペプチダーゼｉｖ阻害剤でのｉｉ型糖尿病の処置 | |
| JP2007523155A5 (enExample) | ||
| JP2010503688A5 (enExample) | ||
| CA2798259A1 (en) | Nuclear receptor binding agents | |
| JP2010523476A5 (enExample) | ||
| JP2017526716A5 (enExample) | ||
| JP2009530398A5 (enExample) | ||
| JP2007519649A5 (enExample) | ||
| JP2017522352A5 (enExample) | ||
| CN105848650A (zh) | 促进吸烟停止 | |
| AU2011230081A1 (en) | Pharmaceutical composition for the prevention or the treatment of non-alcoholic fatty liver disease and the method for prevention or treatment of non-alcoholic fatty liver disease using the same | |
| JP2010522710A5 (enExample) | ||
| US20240287098A1 (en) | Compositions and methods for treating cancer | |
| JP2015536997A5 (enExample) | ||
| CA2608163A1 (en) | Hydralazine compositions and methods | |
| JP2008530242A5 (enExample) | ||
| CN110869030A (zh) | 用于预防及治疗糖尿病性肾病的包含腺苷衍生物的药学组合物 | |
| RU2611623C2 (ru) | Производное 4-фенилпирролидинона-2, содержащая его композиция с ноотропной активностью, способ их получения и способ лечения или профилактики нарушений нервной системы |